uploads///Chart

Merck’s Immunology and Cardiovascular Products in 4Q17

By

Feb. 16 2018, Updated 9:02 a.m. ET

Immunology and cardiovascular products

Merck & Co.’s (MRK) immunology products include Simponi and Remicade. The company’s cardiovascular products include Zetia, Vytorin, Adempas, and Atozet. The chart below shows revenues for key products from immunology and cardiovascular franchise over last few quarters.

Article continues below advertisement

Immunology franchise

Remicade is a drug marketed by Johnson & Johnson (JNJ) in major countries outside Europe and marketed by Merck & Co. in major European markets. Remicade reported revenues of $186.0 million in 4Q1 for a 31.0% decline compared to $269.0 million in 4Q16. The decline in revenues for Remicade was due to lower sales of the drug following competition from generic products and biosimilars.

Simponi reported revenues of $217.0 million in 4Q17, representing 17.0% growth in revenues compared to $186.0 million in 4Q16.

Cardiovascular franchise

Merck & Co.’s cardiovascular portfolio comprises Zetia, Vytorin, Adempas, and Atozet. Zetia and Vytorin are used for lowering LDL cholesterol levels. The combined revenues for Zetia and Vytorin fell 42.0% to $509.0 million in 4Q17, compared to $873.0 million in 4Q16. 

Zetia reported revenues of $323.0 million in 4Q17, a 44.0% decline compared to $575.0 million in 4Q16. Vytorin reported revenues of $186.0 million in 4Q17, a 38% decline in revenues compared to $299.0 million in 4Q16.

Adempas’s revenues increased to $79.0 million in 4Q17, representing 63.0% growth in revenues compared to $49.0 million in 4Q16. Atozet’s revenues increased to $54.0 million in 4Q17, representing 7.0% growth compared to $50.0 million in 4Q16. The competing cardiovascular drugs include Pfizer’s (PFE) Lipitor and AbbVie’s (ABBV) Niaspan.

Advertisement

More From Market Realist

  • Honeywell sign
    Earnings Report
    CNBC Pro Stocks to Buy Before Q1 Earnings
  • Men walking by Morgan Stanley headquarters
    Financials
    Morgan Stanley’s (MS) Stock Forecast Before Q1 Earnings
  • Carnival cruise ship sailing
    Consumer
    Carnival's (CCL) Stock Forecast Before Q1 Business Update
  • GameStop store
    Consumer
    GME's Earnings Are Coming: Will It Be Mayday for Shorts or WallStreetBets?
  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.